What happened

Anthropic's October 27 research post says its scientists have worked with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Generate says six of its scientists used Claude Code on one part of a cancer-therapy design. One result was about 70 percent shorter than the standard version, and lab tests showed immune cells making roughly 10 times as many receptors. Divergence says Claude produced about 35,000 antibody designs in about a month, and early tests found hits. BigHat says the lab made and tested about 1,010 variants in about 10 weeks. The best versions bound more than 10 times more tightly, one stayed in solution 18 degrees higher, and one clumped more than 100 times more slowly. Enveda says a check of 1,061 documentation pages caught all 11 issues human reviewers had found and flagged seven more, and cut review time by 89 percent, from over 25 hours to under three. A first draft of one regulatory document took four hours, against about three months by hand. The Column Group's new company, Pleiades, has evaluated one Claude skill on 45 target-disease pairs. Anthropic says a program it acquired went from an idea to results in mice in under 18 months, and that a human trial is not expected before late 2028. Work with Bristol Myers Squibb on clinical-trial planning is set to expand in 2027.

Why it matters

A lab is now publishing partner numbers for Claude inside drug programs, not only a model card. The numbers are large, and Anthropic's own sentence puts them before human testing. A shorter design and a faster document review are different jobs from a drug that has been shown to work in people.

Enveda's 89 percent cut is review time on manufacturing documents, from over 25 hours to under three. It is not a claim about how well a drug works.

The Column Group figure is an evaluation of one skill on 45 target-disease pairs. Anthropic does not print how many of those pairs the skill got right.

Anthropic says the Bristol Myers Squibb work on trial planning expands in 2027. That date is a plan, not a result.